Lv4
650 积分 2023-02-17 加入
Measurable residual disease-guided interventions in patients with acute myeloid leukaemia undergoing allogeneic haematopoietic cell transplantation: best practice recommendations from the European Society for Blood and Marrow Transplantation Practice Harmonisation and Guidelines Committee
2个月前
已完结
[Research progress on pathogenic germline mutations in malignant tumors]
4个月前
已完结
Additivity predicts the efficacy of most approved combination therapies for advanced cancer
5个月前
已完结
Measurable residual disease (MRD) testing for acute leukemia in EBMT transplant centers: a survey on behalf of the ALWP of the EBMT
6个月前
已完结
The evolving nosology of myeloid neoplasms: the semi-centennial of the 1976 French-American-British classification
6个月前
已完结
Measurable residual disease‐guided therapy in acute myeloid leukaemia: Practical insights
7个月前
已完结
Measurable Residual Disease Monitoring in Acute Myeloid Leukaemia: Techniques, Timing and Therapeutic Implications
7个月前
已完结
Optimal prognostic threshold for measurable residual disease positivity by multiparameter flow cytometry in acute myeloid leukemia (AML)
8个月前
已完结
High risk of thrombosis recurrence in patients with homozygous and compound heterozygous factor V R506Q (Factor V Leiden) and prothrombin G20210A
10个月前
已关闭
皖公网安备34019202002308
